Vanguard Capital Management
CYTK icon

Vanguard Capital Management’s Cytokinetics CYTK Stock Holding History

Vanguard Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$521M Buy
6,117,515
+628,881
+11% +$45.2M 0.01% 691
2026
Q1 		$362M Buy
+5,488,634
New +$349M 0.01% 776

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Capital Management's CYTK Position: Q2 2026 in Review

Vanguard Capital Management increased its Cytokinetics (CYTK) stake by 11% in Q2 2026, buying an estimated $45.2M and bringing the position to 6,117,515 shares worth $521M. The position accounts for 0.01% of the portfolio, ranked #691.

Vanguard Capital Management first reported a position in CYTK in Q1 2026 and has held it in 2 quarters since. 447 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Vanguard Capital Management held 6,117,515 shares of Cytokinetics worth $521M as of Q2 2026.
  • Vanguard Capital Management bought 628,881 Cytokinetics shares in Q2 2026, an estimated $45.2M.
  • Cytokinetics made up 0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #691 holding.
  • Vanguard Capital Management first reported a position in Cytokinetics in Q1 2026 and has held it in 2 quarters since.
  • 447 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.